BES_Mark.jpg
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm
January 23, 2020 14:25 ET | Bragar Eagel & Squire
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Cardinal Health, Inc....
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Valaris, Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm
October 15, 2019 20:37 ET | Bragar Eagel & Squire
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Valaris Plc (NYSE: VAL),...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm
October 09, 2019 08:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm
October 02, 2019 21:07 ET | Bragar Eagel & Squire
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
Schall Firm Logo 2.jpg
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 24, 2019 09:45 ET | Schall Law
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) --  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
Schall Firm Logo 2.jpg
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 17, 2019 10:21 ET | Schall Law
LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
Schall Firm Logo 2.jpg
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 09, 2019 10:56 ET | Schall Law
LOS ANGELES, Sept. 09, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
Scott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta Therapeutics, Inc.
March 28, 2017 11:41 ET | Scott + Scott, Attorneys at Law, LLP
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta...
Summit Master_rgb_png.png
Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 04, 2016 07:01 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 04, 2016 07:00 ET | Summit Therapeutics PLC; Sarepta Therapeutics
Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related...